News
Editor's picks
Latest headlines
A European Standard Clinical Practice Guidance has been published in the European Journal of Endocrinology on the diagnosis and treatment of adrenal and extra-adrenal paragangliomas in children and adolescents.
Treatment with a C-type natriuretic peptide prodrug significantly increases annualised growth velocity in children with achondroplasia and offers additional health benefits, say the APPROACH trial investigators.
US researchers have created age- and sex-adjusted growth charts for use in children with classic congenital adrenal hyperplasia, reflecting the distinct patterns of height and weight among patients versus the general population.
Italian clinicians have published a set of consensus statements on the multidisciplinary diagnosis, care and treatment of patients with Noonan syndrome from childhood and beyond.
Earlier age at diagnosis of childhood differentiated thyroid cancer is associated with a greater risk of advanced disease, but overall, patients have excellent long-term survival irrespective of age, stage, and treatment response, US study findings indicate.
Children with osteogenesis imperfecta are more likely to use anti-fracture drugs than their older counterparts, but underuse is common across all age groups, US study findings indicate.
The first 2 years of recombinant growth hormone therapy offers significant benefits for prepubertal children with Silver–Russell syndrome, French researchers have found.
Plasma and urine analyses are both reliable screening tests for the diagnosis of phaeochromocytoma/paraganglioma in children and adolescents, report researchers in Clinical Endocrinology.
Treatment with recombinant human insulin-like growth factor-1 enables children and adolescents with severe growth failure due to primary IGF-1 deficiency to reach near-adult height, suggest real-world registry data.
An artificial intelligence-assisted tool can speed up anthropometric calculations for paediatric endocrinologists monitoring growth in children with achondroplasia, research indicates.
Genetic testing has identified a likely cause for nonfamilial tall stature in 11% of children examined, show study findings published in the European Journal of Pediatrics.
Research from the Netherlands suggests that the majority of children heterozygous for pathogenic alterations to the NPR2 gene, resulting in mild skeletal dysplasia, respond to growth hormone therapy.
